Clinical trials: Psoriasis Patients
Plaque Psoriasis
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
- Trial name
- SAIL (NCT04203693)
- Testing
- Tildrakizumab
- Where
- 41 sites in Austria, Belgium and 4 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Psoriasis Vulgaris
Safety and Efficacy of Combining nbUVB to Etanercept in Patients
This study will provide data on the addition of narrow band ultra violet B (nbUVB) phototherapy to participants who have not shown an excellent response to three months of etanercept.
- Trial name
- NCT00640393
- Testing
- Etanercept, nbUVB
- Where
- 10 sites in Canada
- Volunteers
- 99 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis
Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.
- Trial name
- NCT00617994
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Incyte Corporation
Psoriasis
Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
Evaluate (i) safety of etanercept in patients with moderate to severe psoriasis in Spain; (ii) the incidence of adverse events reported in these patients, and (iii) the role that age and concomitant therapy might play in the…
- Trial name
- NCT00581165
- Testing
- Etanercept
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.
- Trial name
- Ixora-peds (NCT03073200)
- Testing
- Ixekizumab, Etanercept
- Where
- 69 sites in United States, Argentina and 11 more
- Volunteers
- 201 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis, Psoriasis
Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the…
- Trial name
- NCT03506477
- Testing
- Enstilar® foam, Vehicle foam
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
This is a multi-center, randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT05600036
- Testing
- ESK-001
- Where
- 53 sites in United States, Canada and 1 more
- Volunteers
- 228 people
- Sponsor
- Alumis Inc
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Sleep Disturbance
• Sleep Disturbance Among Patients With Psoriasis and Atopy and Comparison Between Them
Comparison between sleep disturbance in atopy and psoriasis and control
- Trial name
- NCT03864809
- Testing
- sleep disturbance
- Volunteers
- 150 people
- Sponsor
- Assiut University
Psoriasis
Efficacy and Safety of Apremilast in Psoriasis
Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications.
- Trial name
- NCT06032858
- Testing
- Apremilast 30mg
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Ghurki Trust and Teaching Hospital
Rheumatoid Arthritis, Inflammatory Rheumatism
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
Janus kinase (JAK) inhibitors are a new class of molecules available to the therapeutic arsenal for chronic inflammatory rheumatic diseases.The tolerance profile of this new class needs to be better defined and its use in real…
- Conditions
- Rheumatoid Arthritis, Inflammatory Rheumatism, Psoriatic Arthritis, Spondyloarthritis
- Trial name
- MAJIK (NCT04602091)
- Testing
- no intervention
- Where
- 60 sites in France
- Volunteers
- 2,300 people
- Sponsor
- Societe Francaise de Rhumatologie
Psoriasis
Assessment of the Effect of a Dermatology-Oriented Spa Therapy on the Quality of Life of Patients With Psoriasis
Evaluation of the effect of a dermatology-oriented spa therapy at 4.5 months on the quality of life of patients suffering from psoriasis
- Trial name
- BAREGES (NCT06735911)
- Testing
- Spa therapy
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Thermes de Bareges
Psoriatic Arthritis
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
This study was designed as a 3-year extension to the phase III core study CAIN457F2306. It aimed to provide continuous treatment with secukinumab in pre-filled syringes (PFS) for subjects who completed the core study…
- Trial name
- FUTURE 1 ext (NCT01892436)
- Testing
- Secukinumab
- Where
- 94 sites in United States, Argentina and 16 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Psoriasis Arthritis
Psoriasis Comorbidities at Hospital Calderón Guardia
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025.
- Conditions
- Psoriasis, Psoriasis Arthritis, Psoriasis (PsO), Psoriasis Patients
- Trial name
- NCT07448337
- Where
- Costa Rica
- Volunteers
- 350 people
- Sponsor
- Caja Costarricense de Seguro Social
Arthritis, Psoriatic
Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions
A total of approximately 500 patients with active psoriatic arthritis in an estimated 80 to 100 trial centers are to be enrolled. Selection of centers will be made by the sponsor's medical section.
- Trial name
- LAPIS-PsA (NCT03106051)
- Where
- 2 sites in Germany
- Volunteers
- 526 people
- Sponsor
- Amgen
Psoriasis
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive…
- Trial name
- NCT00778700
- Testing
- Ruxolitinib Phosphate
- Where
- 28 sites in United States
- Volunteers
- 199 people
- Sponsor
- Incyte Corporation
Psoriatic Arthritis
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.
- Trial name
- NCT02267642
- Testing
- AbGn-168H
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Psoriasis
Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin
Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients
- Trial name
- NCT05203354
- Testing
- Narrowband Ultraviolet B, Acitretin
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mahmoud Ahmed Ali Ahmed
Plaque Psoriasis
A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
IMO 8400 is a second-generation oligonucleotide antagonist of endosomal Toll-like receptors (TLR) 7, TLR8 and TLR9. These TLR react to complexes of exogenous nucleic acids (as might be encountered during infection) and endogenous…
- Trial name
- 8400-201 (NCT01899729)
- Testing
- IMO-8400 Regimen 1, IMO-8400 Regimen 2, IMO-8400 Regimen 3
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Idera Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.